--- tags: - chemistry - biology pretty_name: A-Alpha Bio open source data size_categories: - 10K 50 % of replicate samples. A value of False suggests a potentially spurious or unreliable interaction. | ## FAQ Please see below for some clarifying details: ### Where can I find experimental details for each dataset? Each dataset has a corresponding README.md in its subfolder summarizing the experiment's goals, library composition, and citation info. See `./data/YM_0005/README.md` for an example. ### What kind of sequences are in the library? While not a strict rule, the A-libraries typically contain designed sequences, while the Alpha-libraries contain corresponding targets of interest. Historically, we’ve used VHHs or scFvs in the A-library and antigen targets in the Alpha-library. Each dataset will have a card that details specific information of the individual assay run. When building or training models, note that PPIs can generally be treated as symmetric. However, members within the same library may share sequence, functional, or structural similarities. Also, some models are sensitive to input order — so ensure that (A, Alpha) pairs are treated consistently between training and testing. ### Why are there duplicate PPIs in the dataset? Some datasets include technical replicates, often for the wild-type (“WT”) or parent sequence in mutation studies. Replicates help capture the experimental and biological variation in measured affinities. This can be useful for analyses that assess the statistical significance of observed affinity difference, such as identifying how much a vaiant changes binding strength relative to a parent protein. ### What is considered a strong or good binder? Affinity measurements are reported in log10 Kd nM (a value of 0 indicates 1 nM, 3 is 1 uM, 5 is 100 uM). Lower values indicate stronger binding. In practice, we often compare relative affinities - for example, assessing differences in binding strength as a target interface is mutated, or comparing variant binders to their parent. ### The dataset has NaN values in the affinity, why? Not all PPIs form detectable interactions; weak or non-binding interactions may result in no paired barcode reads, yielding NaN values. For these cases, it may be more useful to look at the lower or upper bound affinities to help interpret the range of possible affinity within the assay. ### What do Iter0 / Iter1 mean? Iter0 and Iter1 (abbreviated for Iteration) are our nomenclature for describing antibody variant libraries designed for antibody optimization campaigns. Iter0 libraries are generated in a zero-shot fashion (ie random mutations or selections by ESM) while Iter1 libraries are generated with models trained on Iter0 datasets. ### How should I cite this dataset? To properly acknowledge this work, please cite: 1. **This dataset repository:** ```text A-Alpha Bio (2025). Open Protein–Protein Interaction Affinity Datasets with AlphaSeq. https://huggingface.co/datasets/aalphabio/open-alphaseq ``` 2. **The AlphaSeq technology paper:** ```text Younger, D., Berger, S., Baker, D., & Klavins, E. (2017). High-throughput characterization of protein–protein interactions by reprogramming yeast mating. Proceedings of the National Academy of Sciences, 114(46), 12166-12171. https://doi.org/10.1073/pnas.1705867114 ``` 3. **The specific experiment paper(s) for the dataset(s) you use:** - **If using YM_0005:** Cite the CoV epitope mapping paper (Engelhart et al., 2022) - see [References](#references) section - **If using any other experiments (YM_0549, YM_0693, YM_0852, YM_0985, YM_0988, YM_0989, YM_0990, YM_1068):** Cite the AlphaBind paper (2025) - see [References](#references) section For complete citation details and DOI links, see the [References](#references) section above. ### Can I use this dataset for model training or benchmarking? Yes — the dataset is released fully open source, and is suitable for both academic and commercial use. ### Who can I contact with questions or feedback? Feel free to email maintainers [Natasha Murakowska](mailto:nmurakowska@aalphabio.com) or [David Noble](mailto:dnoble@aalphabio.com). We will host a discussions tab for open discourse as well.